US19240Q2012 - Common Stock
COGENT BIOSCIENCES INC
NASDAQ:COGT (3/28/2024, 7:04:54 PM)
After market: 6.72 0 (0%)6.72
+0.2 (+3.07%)
Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. The company is headquartered in Waltham, Massachusetts and currently employs 138 full-time employees. The company went IPO on 2018-03-29. The Company’s advanced clinical program, bezuclastinib (CGT9486), is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17 found within the KIT receptor tyrosine kinase, including KIT D816V. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases. The firm has initiated APEX, a Phase II clinical study of bezuclastinib in patients with AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.
COGENT BIOSCIENCES INC
275 Wyman Street, 3rd Floor
Waltham MASSACHUSETTS 02140
P: 16179455576
CEO: Andrew Robbins
Employees: 138
Website: https://www.cogentbio.com/
Baird downgrades Cogent Biosciences to neutral as disappointing data for bezuclastinib raises concerns. Read more here.
• UMMIT Part 2 registration-directed study of bezuclastinib in NonAdvSM patients initiated and actively enrolling at 40 sites globally; once-daily 100 mg...
Cogent Biosciences (COGT) stock jumped 10% Thursday after the company reported positive data for its drug candidate bezuclastinib in the treatment of NonAdvSM. Read more here.
Registration-enabling SUMMIT Part 2 initiated and actively enrolling at 40 sites globally; RP2D selected at 100 mg once-daily optimized formulation based...
Cogent Biosciences has entered into a private investment in public equity financing, raising $225 million to fund R&D activities and general corporate...
Here you can normally see the latest stock twits on COGT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: